Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Detrol LA combined with standard treatment for enlarged prostate is twice as effective

05.11.2004


In relieving overactive bladder as standard treatment alone



Combination therapy with Pfizer Inc’s DETROL® LA (tolterodine tartrate extended release capsules) and an alpha blocker, a standard treatment for enlarged prostate, was twice as effective in relieving overactive bladder (OAB) symptoms as the alpha blocker alone in men with both bladder obstruction and OAB, according to a study published in the October issue of the British Journal of Urology. Six million American men suffer from a combination of a common complication of enlarged prostate called bladder outlet obstruction, which reduces or prevents urine flow, and OAB, a medical condition associated with involuntary contractions of the bladder muscle.

"There is overlap in the symptoms of bladder outlet obstruction and overactive bladder, so current clinical practice entails treating bladder obstruction first, and adding a therapy like DETROL LA only if the man continues to suffer for several months from urgency, frequency and excessive urination at night," said study author Dr. Michael Chancellor, professor of urology at the University of Pittsburgh. "These findings suggest that combination therapy is well tolerated and can be considered for men with or without bladder obstruction."


The prospective study divided 144 men into two groups, those with bladder obstruction only (n=76) and those with bladder obstruction plus OAB (n=68). All patients were treated with alpha blocker doxazosin for three months. In patients with no symptomatic improvement, DETROL LA was added for an additional three months. Seventy-three percent of men with bladder obstruction and OAB reported an improvement during the combination therapy phase of the study compared to 35 percent reporting improvement in the initial doxazosin alone phase.

The most common side effects of doxazosin were dizziness, postural hypotension and abnormal ejaculation. The most common side effect of DETROL LA was dry mouth. There was a low incidence (3.3 percent) of transient urinary retention in men who received combination therapy. The transient urinary retention was resolved within 24 hours after stopping treatment.

About Overactive Bladder

An estimated 33 million Americans over the age of 18 suffer from OAB. A person with overactive bladder will feel a sudden and sometimes overwhelming urge to urinate (urgency). This is because the bladder muscle squeezes or contracts at a small volume and without the normal warning signals that capacity is being reached. This usually results in more frequent urination (frequency), and sometimes, wetting accidents (urge incontinence).

Treatment

Once overactive bladder is diagnosed, muscarinic receptor antagonists, the mainstay of medical treatment for overactive bladder, may be prescribed. One such medication, DETROL LA works by helping to control involuntary contractions of the bladder muscle. Behavioral techniques such as pelvic floor muscle exercises, or bladder training may provide additional benefit to the medication by helping the patient reassert control over his or her bladder.

About DETROL LA

DETROL LA is a once-daily medication with proven efficacy for 24 hours to help control bladder contractions and reduce wetting accidents and voiding accidents. DETROL LA reduces the number and intensity of involuntary bladder muscle contractions, and also reduces the strong urinary urgency associated with overactive bladder.

Since its introduction in January 2001, DETROL LA has become the number one prescribed treatment for overactive bladder in the United States and has been prescribed for more than seven million patients worldwide.

DETROL LA is indicated for the treatment of overactive bladder with symptoms of urge incontinence, urgency and frequency.

DETROL LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug or its ingredients.

Patients with the following conditions should be treated with caution: renal impairment, bladder outflow obstruction*, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, and significantly reduced hepatic function. Dry mouth was the most frequently reported adverse event (DETROL LA 23 percent vs. placebo 8 percent); others (> 4 percent) included headache (DETROL LA 6 percent vs. placebo 4 percent), constipation (DETROL LA 6 percent vs. placebo 4 percent), and abdominal pain (DETROL LA 4 percent vs. placebo 2 percent).

*While bladder obstruction is a precaution to the use of DETROL LA, in this study all men received doxazosin for treatment of the obstruction prior to adding DETROL LA and only two men (3.3%) on combination therapy developed transient urinary retention, which resolved within 24 hours after stopping treatment.

Rebecca Hamm | EurekAlert!
Further information:
http://www.pfizer.com

More articles from Health and Medicine:

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Better equipped in the fight against lung cancer
16.05.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

Im Focus: Computer-Designed Customized Regenerative Heart Valves

Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.

Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...

Im Focus: Light-induced superconductivity under high pressure

A team of scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg investigated optically-induced superconductivity in the alkali-doped fulleride K3C60under high external pressures. This study allowed, on one hand, to uniquely assess the nature of the transient state as a superconducting phase. In addition, it unveiled the possibility to induce superconductivity in K3C60 at temperatures far above the -170 degrees Celsius hypothesized previously, and rather all the way to room temperature. The paper by Cantaluppi et al has been published in Nature Physics.

Unlike ordinary metals, superconductors have the unique capability of transporting electrical currents without any loss. Nowadays, their technological...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Supersonic waves may help electronics beat the heat

18.05.2018 | Power and Electrical Engineering

Keeping a Close Eye on Ice Loss

18.05.2018 | Information Technology

CrowdWater: An App for Flood Research

18.05.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>